News - Ipsen, Inflammatory diseases

Filter

Popular Filters

1 to 25 of 118 results

Glenmark gets $4 million milestone in Forest collaboration

Glenmark gets $4 million milestone in Forest collaboration

27-03-2014

Indian drugmaker Glenmark Pharmaceuticals has informed the Stock Exchange today that the company through…

FinancialForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingPharmaceutical

Insmed’s mixed results from Ph II trial for treatment resistant NTM lung infections

27-03-2014

US-based Insmed has reported mixed results from its Phase II clinical trial of Arikayce, for the treatment…

Inflammatory diseasesInsmedPharmaceuticalRegulationRespiratory and PulmonaryUSA

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Ipsen returns to profit, with drug sales up 2.1%

28-02-2014

Full-year 2013 group revenues at French drugmaker Ipsen came in at 1.28 billion euros ($17.59 billion),…

FinancialIpsenPharmaceutical

Ipsen posts top results for Phase III study of Decapeptyl in prostate cancer

Ipsen posts top results for Phase III study of Decapeptyl in prostate cancer

07-02-2014

French drugmaker Ipsen has announced that the Phase III clinical trial evaluating Decapeptyl (triptorelin…

DecapeptylFranceIpsenOncologyPharmaceuticalResearch

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

05-02-2014

French drugmaker Ipsen today announced the results of the international Phase III clinical trial of Dysport…

DysportFranceGeneticsIpsenPharmaceuticalResearch

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

Ipsen’s sales grow 2.2% in 2013, but miss expectations

Ipsen’s sales grow 2.2% in 2013, but miss expectations

28-01-2014

French drugmaker Ipsen posted solid sales growth for fourth-quarter and full-year 2013, though there…

FinancialIpsenPharmaceutical

Ipsen, a good European mid-cap to watch, says US analyst

Ipsen, a good European mid-cap to watch, says US analyst

27-01-2014

Most American investors are familiar with large European drugmakers like Sanofi and Novartis but the…

FinancialIpsenOncologyPharmaceuticalResearchSomatulinetasquinimod

Ipsen implements new US governance to prepare for Somatuline launch in oncology

Ipsen implements new US governance to prepare for Somatuline launch in oncology

22-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision…

BoardroomIpsenOncologyPharmaceuticalSomatulineUSA

Ipsen reveals positive results for Somatuline

Ipsen reveals positive results for Somatuline

17-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced that Somatuline Autogel/Somatuline Depot (lanreotide)…

FranceIpsenOncologyPharmaceuticalResearchSomatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

14-01-2014

French drugmaker Ipsen (Euronext: IPN) and UK-based GW Pharmaceuticals (Nasdaq: GWPH) have entered into…

FranceGW PharmaceuticalsIpsenLicensingPharmaceuticalSativexSomatuline

NovaSAID partners with Cadila to develop inflammation and pain therapies

10-01-2014

Swedish research based company NovaSAID (a Karolinska Development portfolio firm) and Cadila Pharmaceuticals,…

Cadila PharmaceuticalsInflammatory diseasesNeurologicalNovaSAIDPharmaceuticalResearch

Ipsen recruits executive VP, technical operations

Ipsen recruits executive VP, technical operations

10-01-2014

French drugmaker Ipsen has appointed Jonathan Barnsley as executive vice president in charge of technical…

BoardroomIpsenManagementPharmaceutical

Shield Therapeutics’ ST10 delivers robust results in AEGIS Ph III program

07-01-2014

Independent UK pharma firm Shield Therapeutics has announces strongly positive top-line data from the…

HematologyInflammatory diseasesPharmaceuticalResearchShield TherapeuticsST10

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

06-01-2014

Privately-held German company Probiodrug says it has transferred its experimental cyclin-dependent kinase…

AstraZenecaInflammatory diseasesMergers & AcquisitionsOncologyPharmaceuticalProbiodrug

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

19-12-2013

French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice…

BoardroomEuropeIpsenNeurologicalOncologyPharmaceutical

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

17-12-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive initial results from a Phase III study…

DysportIpsenNeurologicalNorthern EuropePharmaceuticalResearch

Ampio Pharma takes spin-out route on failure to find Zertane partner

Ampio Pharma takes spin-out route on failure to find Zertane partner

16-12-2013

US drug developer Ampio Pharmaceuticals announced that it has spun off its sexual dysfunction business…

Ampio PharmaceuticalsAmpionInflammatory diseasesMen's HealthMergers & AcquisitionsPharmaceuticalProductionVyrix PharmaceuticalsZertane

AstraZeneca lesinurad meets Ph III goal in gout patients

AstraZeneca lesinurad meets Ph III goal in gout patients

16-12-2013

Anglo-Swedish drug major AstraZeneca has released positive top-line results from LIGHT, a Phase III…

Anti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

1 to 25 of 118 results

Company Spotlight

Fibrotech

Fibrotech

Back to top